Icon
+91 94997 68112
Login Register

DAURISMO - (EQ 25MG BASE,EQ 100MG BASE ; Tablet)

GLASDEGIB MALEATE Pfizer
EQ 25MG BASE,EQ 100MG BASE ; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
None None
DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Yes
DAURISMO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********
************* *********** ************* *********** *********** ***** ** *-((**,**)-*-(**-*****[*]********-*-**)-*-***************-*-**)-*-(*-***********)**** ******* *********** ***** ** *-((**,**)-*-(**-*****[*]********-*-**)-*-***************-*-**)-*-(*-***********)**** ******* *********** ***** ** *-((**,**)-*-(**-*****[*]********-*-**)-*-***************-*-**)-*-(*-***********)**** *******

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.